L ong noncoding RNAs (lncRNAs) are a class of transcripts with diverse and largely uncharacterized biological functions [1] [2] [3] . Through crosstalk with chromatin, DNA, RNA species and proteins, lncRNAs function via chromatin remodeling, as well as transcriptional and post-transcriptional regulation [4] [5] [6] [7] [8] [9] . High-throughput RNA sequencing (RNA-seq) has enabled the identification of lncRNAs with suggested oncogenic and tumor-suppressive roles, including involvement in the pathogenesis of prostate cancer 7,10-12 . Primary prostate cancer is often hormone dependent and relies on signaling through the AR; therefore, the majority of patients are responsive to front-line treatment with androgen-deprivation therapy [13] [14] [15] . However, approximately 20% of cases progress to an incurable stage of the disease known as castration-resistant prostate cancer (CRPC), which still critically relies on AR signaling 16, 17 , as evidenced by the clinical benefit afforded through the use of enzalutamide [18] [19] [20] [21] or abiraterone [22] [23] [24] . While substantial efforts have been undertaken to identify mechanisms of sustained AR signaling in CRPC (i.e., AR alterations, AR splice variants and alternative activation pathways) [25] [26] [27] [28] [29] [30] [31] , few studies have investigated the role of AR-regulated lncRNAs. Therefore, we initiated a comprehensive RNA-seq profiling investigation of AR-regulated, cancer-associated lncRNAs from prostate cancer cell lines and patient tissue samples.
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24 h ( Supplementary Fig. 1a ). A total of 1,702 genes were identified to be concordantly induced or repressed in VCaP and LNCaP cells at both time points ( Fig. 1a, Supplementary Fig. 1b,c and Supplementary Table 1 ), including more than 500 lncRNAs ( Fig. 1a and Supplementary Fig. 1d ); these data indicate that a large portion of the AR transcriptome remains uncharacterized.
To differentiate between direct and indirect ARGs, previously published and in-house AR chromatin immunoprecipitation (ChIP)-seq data from LNCaP and VCaP cells were analyzed 32 . As expected for direct AR targets, increased levels of AR binding at transcription start sites (TSSs) in both LNCaP and VCaP cells were observed ( Supplementary Fig. 1e ). The binding levels decreased following treatment with an AR antagonist (enzalutamide) ( Supplementary Fig. 1f,g) , and the binding sites revealed a de novo motif identical to the canonical AR response element 33 ( Supplementary Fig. 1h ). A total of 987 genes were categorized as direct ARGs, including 341 lncRNAs (lncARGs) (Supplementary Table 1 ). Within these genes, we observed an enrichment of chromatin marks associated with 'open' chromatin (H3K27ac, H3K4me1), active promoters (H3K4me3) and transcription (H3K36me3), which, together with RNA polymerase II (Pol II) occupancy, are recognized as manifestations of active gene expression ( Supplementary Fig. 1i ). Bromodomain and extra-terminal (BET) family proteins, such as BRD4, recognize acetylated histones and have been shown to promote AR transcriptional activity 32 . Consistent with this, we observed colocalization of BRD4 and AR proteins at the promoters of direct AR-responsive genes and loss of AR ChIP peaks following treatment with a bromodomain inhibitor (JQ1) ( Supplementary Fig. 1f ,i). We further sought to determine whether ARGs identified from cell lines were also targeted by AR in normal prostate tissues and primary tumors. We leveraged a published dataset 34 and queried for the presence of AR peaks within ARG promoters. Remarkably, the majority of ARG promoters were TSS-proximally bound by AR in both tissues and cell lines ( Supplementary Fig. 1j,k) ; conversely, AR-independent genes were distal to AR-binding sites ( Supplementary Fig. 1l ).
Finally, we confirmed that the ARGs were also expressed in human prostate tissues. We interrogated RNA-seq data from normal prostate, clinically localized prostate cancer (The Cancer Genome Atlas, TCGA) 35 and metastatic CRPC (Stand Up to Cancer-Prostate Cancer Foundation, SU2C-PCF) 30 (Fig. 1b ). This revealed remarkable heterogeneity in the expression of ARGs during prostate cancer progression to metastatic disease. As expected, compared to protein-coding genes, noncoding ARGs were detected at lower overall levels ( Fig. 1c ), although ~10% showed robust expression of over 10 FPKM (fragments per kilobase of transcript per million mapped reads) on average across prostate cancer samples. 
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ARLNC1 is a prostate lineage-specific lncRNA with elevated expression in cancer. We hypothesized that lncRNAs associated with prostate cancer progression and castration resistance should be either upregulated if they enhance AR signaling or, conversely, downregulated if they attenuate AR signaling. Their expression is also expected to be AR dependent and lineage restricted if they are part of bona fide physiological feedback loops. Accordingly, a top-down strategy was developed to establish and prioritize clinically relevant, prostate cancer-and lineage-specific lncARGs. First, we identified genes that were both regulated by AR in the VCaP and LNCaP cell lines and upregulated in primary ( Fig. 2a ) or metastatic ( Fig. 2b ) prostate cancer as compared to normal prostate tissues. As expected, canonical AR targets, including KLK3, KLK2 and TMPRSS2, were among the most differentially expressed protein-coding genes. Notably, this approach highlighted several novel lncARGs, including ARLNC1 (ENSG00000260896, PRCAT47 10 ), and validated previously identified lncARGs, such as CTBP1-AS 36 (Fig. 2a,b ). Interestingly, ARLNC1 was found to be one of the most differentially expressed AR-regulated genes in both localized and metastatic prostate cancer ( Fig. 2a,b and Supplementary Fig. 2a,b ). Next, we sought to establish the prostate lineage and cancer specificity of prostate cancer-associated lncRNAs. We leveraged the MiTranscriptome assembly 10 , an online resource, to interrogate lncRNA expression across a multitude of tissue and tumor types, and we calculated sample set enrichment analysis (SSEA) scores, which indicate the strength of cancer and lineage association 10 . After applying an expression-level filter (10 FPKM at the 95th percentile), we identified 12 of the most prostate lineage-and cancer-specific lncRNAs ( Fig. 2c and Supplementary Fig. 2c,d) ; 5 of these lncRNAs were regulated by AR. Across these analyses, ARLNC1 was the top prioritized transcript and thus warranted further investigation. Fig. 1a . The y axis depicts the log 2 -transformed fold change in gene expression following DHT stimulation, and the x axis indicates the log 2 -transformed difference in gene expression level between benign prostate (n = 52 samples) and localized prostate cancer (n = 500 samples) (a) and between benign prostate (n = 52 samples) and metastatic prostate cancer (n = 100 samples) (b). Significant genes with log 2 fold change > 1 were ranked according to combined P value (limma-moderated t test). c, Nomination of prostate cancer-and lineage-associated lncRNAs based on expression levels. The scatterplot shows the expression level, prostate tissue specificity and prostate cancer association of lncRNAs. The expression level is the FPKM value at the 95th percentile across TCGA prostate samples. Average cancer and lineage associations are represented by the percentile rank for each gene in SSEA (total n = 7,256 samples). d, Relative expression (FPKM) of ARLNC1 across different cancer types in the TCGA cohort. Inset, relative expression (FPKM) of ARLNC1 across benign prostate (n = 52 samples), localized prostate cancer (n = 500 samples) and metastatic prostate cancer (n = 100 samples). PCa versus Normal: ****P < 2.2 × 10 −16 ; Mets versus Normal: ****P = 2.6 × 10 −7 (two-sided t test). Box-plot definitions: the center line depicts the median, the box shows the first and third quartiles, and the whiskers follow the 1.5 rule. e, ISH of ARLNC1 transcript in a human prostate cancer tissue microarray. Representative ARLNC1 staining is shown for benign prostate and localized and metastatic prostate cancer tissue. The bar plot represents mean ARLNC1 expression scores across benign prostate (n = 11), localized prostate cancer (n = 85) and metastatic prostate cancer (n = 37) tissues, with vertical bars indicating the bootstrapped 95% confidence interval of the means. Significance was calculated by a Kruskal-Wallis rank-sum test.
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Expression of ARLNC1 was interrogated across cancer and normal tissue RNA-seq samples from TCGA and the Genotype-Tissue Expression (GTEx) project 37, 38 , respectively. In the TCGA cohort, ARLNC1 exhibited a highly prostate cancer-specific expression pattern, with little to no expression in other tumor types ( Fig. 2d) . Similarly, in the GTEx normal tissue cohort, its expression was limited to the prostate ( Supplementary Fig. 2e ). Among the prostate samples, ARLNC1 expression was significantly higher in localized and metastatic prostate cancers than in benign tissues, as assessed by RNA-seq ( Fig. 2d , inset) and in situ hybridization (ISH; Fig. 2e ). In an extensive differential expression analysis using MiTranscriptome, ARLNC1 was found to be among the top 1% of transcripts most upregulated in prostate cancer and specific to the prostate lineage, with no significant associations in other tissues ( Supplementary  Fig. 2f ). Moreover, the protein-coding genes that were most correlated with ARLNC1 were found to be associated with prostate cancer progression in ONCOMINE concept analyses performed on multiple clinical datasets 39 ( Supplementary Fig. 2g ). Together, these results confirm that ARLNC1 expression is restricted to the prostate lineage, elevated in prostate cancer and associated with AR signaling throughout prostate cancer progression.
To functionally characterize ARLNC1, we first identified appropriate prostate cancer cell lines with moderate to high levels of ARLNC1 expression using in-house RNA-seq data ( Supplementary  Fig. 3a ). Supporting the association of AR with ARLNC1, ARLNC1 expression was highly enriched in AR-positive cell lines, with the highest expression in MDA-PCa-2b and LNCaP cells. In addition, qPCR analysis for the ARLNC1 transcript also demonstrated that this gene was expressed at the highest level in the MDA-PCa-2b and LNCaP cell lines ( Supplementary Fig. 3b ). As existing annotations of the ARLNC1 gene (located on chromosome 16) predict the presence of several transcript isoforms that differ in exon and TSS usage, we determined the exact structure in MDA-PCa-2b and LNCaP cells by RACE. A common TSS for ARLNC1 was found in both cell lines, and the ~2.8-kb transcript isoform was further confirmed by northern blot analysis ( Supplementary Fig. 3c ). Single-molecule FISH (smFISH) revealed that approximately 100 molecules of ARLNC1 transcript existed per MDA-PCa-2b cell ( Supplementary  Fig. 3d ,e). Using smFISH and qPCR, we also found that ARLNC1 molecules were distributed equally between the nuclear and cytoplasmic cellular compartments ( Supplementary Fig. 3f ,g).
ARLNC1 transcription is directly regulated by AR. Because ARLNC1 was identified as an AR-regulated lncRNA, we inspected the promoter region of the ARLNC1 gene for AR occupancy and identified an androgen-induced AR peak in AR ChIP-seq data from both DHT-stimulated VCaP and LNCaP cells ( Fig. 3a) . Notably, this AR-binding site was also observed in prostate tissue samples and contained a canonical androgen response element 33 (Fig. 3a) . These observations were corroborated by ChIP-qPCR in MDA-PCa-2b cells, which showed the highest level of ARLNC1 expression ( Fig. 3b ). Considering the observation that ARLNC1 expression is prostate tissue specific, while AR expression is not as much, we searched for additional regulators (transcription factors and epigenetic modifiers) of the ARLNC1 gene ( Supplementary Fig. 4a ). Motif analysis of the ARLNC1 promoter region identified several transcription factor binding sites, including a FOXA1 response element. To further validate ARLNC1 gene regulation by AR and FOXA1, we evaluated ARLNC1 transcript levels following AR or FOXA1 knockdown. AR or FOXA1 loss resulted in decreased expression of ARLNC1, along with other canonical AR target genes that served as positive controls ( Fig. 3c and Supplementary Fig. 4b ). ChIPseq and ChIP-qPCR analyses additionally confirmed the putative FOXA1-binding motif on the ARLNC1 promoter ( Supplementary  Fig. 4c ). Together, these observations suggest that ARLNC1 is directly regulated by AR and modestly regulated by FOXA1, which partially explains the tissue-specific expression pattern of ARLNC1, as expression of these two transcription factors overlaps nearly exclusively in prostate tissue 37, 38 ( Supplementary Fig. 4d ).
ARLNC1 regulates AR signaling. To elucidate the function of ARLNC1 in prostate cancer, we performed gene expression profiling of wild-type and ARLNC1-knockdown MDA-PCa-2b cells (Fig. 4a ). Gene ontology (GO) pathway enrichment analysis of the differentially expressed genes revealed deregulation of four main biological activities: apoptosis, cell proliferation, DNA damage response and androgen signaling (Fig. 4a ). The significant decrease in AR target gene expression is particularly interesting given the fact that ARLNC1 is regulated by AR, suggesting a positive feedback loop between ARLNC1 and AR signaling. To confirm this observation, we generated an AR target gene signature from MDA-PCa-2b cells stimulated with DHT ( Supplementary Fig. 5a and Supplementary Table 2 ) and performed gene set enrichment analysis (GSEA) using this gene signature (Fig. 4b ). Knockdown 
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of ARLNC1 led to suppression of genes positively regulated by AR and upregulation of genes negatively regulated by AR (Fig. 4b,c and Supplementary Fig. 5b ). This was further confirmed by an AR reporter activity assay ( Fig. 4d and Supplementary Fig. 5c ), as well as qPCR analysis of AR target genes ( Supplementary  Fig. 5d ). Interestingly, ARLNC1 knockdown also had a significant effect on the mRNA and protein levels of AR ( Fig. 4e,f) , suggesting direct regulation of AR by ARLNC1. However, we found that ARLNC1 overexpression did not affect AR and its signaling cascade ( Supplementary Fig. 5e ).
In situ colocalization of ARLNC1 and AR transcripts. Noncoding RNAs have been shown to target mRNAs via direct or indirect RNA-RNA interaction 9, [40] [41] [42] . To identify target mRNAs that could interact with ARLNC1, we performed unbiased prediction of RNA-RNA interactions using IntraRNA 43, 44 . Interestingly, the 3′ UTR of the AR transcript was identified as a target of ARLNC1 ( Fig. 5a and Supplementary Fig. 6a ). An in vitro RNA-RNA interaction assay between the 3′ UTR of AR and full-length ARLNC1 confirmed this in silico prediction (Fig. 5b ). To evaluate this interaction in the context of the cellular environment, multiplexed smFISH for AR and ARLNC1 transcripts was performed in MDA-PCa-2b cells. On co-staining of MDA-PCa-2b cells for either a combination of AR transcripts and a panel of lncRNAs or ARLNC1 and a panel of mRNAs, we observed specific colocalization of AR and ARLNC1 transcripts in the nucleus within foci that were typically larger than individual molecules ( Fig. 5c-e ). The extent of colocalization was much higher than that expected from coincidental colocalization with an abundant transcript, such as MALAT1 or GAPDH (Fig. 5c-e ). More specifically, colocalization typically occurred at a stoichiometry of 2:1 ARLNC1/AR, which accounted for ~10-20% of all AR and ARLNC1 transcripts in the cell ( Supplementary Fig. 6b ). Furthermore, AR-ARLNC1 colocalization was observed in ARLNC1-positive prostate cancer tissues (Fig. 5f,g) . GO Supplementary Fig. 9 .
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Using an in vitro RNA-RNA binding assay, we identified nucleotides 700-1300 of ARLNC1 to be critical for binding to the AR 3′ UTR (Fig. 6a,b ). To confirm this observation within the cellular context, we ectopically overexpressed different fragments of ARLNC1 together with AR in U2OS osteosarcoma cells. In this exogenous system, colocalization of AR and ARLNC1 was once again demonstrated, wherein colocalization was dependent on the presence of nucleotides 700-1300 of ARLNC1 (Fig. 6c,d and Supplementary Fig. 6c ). Furthermore, incubation with antisense oligonucleotides (ASOs) that blocked the interaction site led to a significant reduction in ARLNC1-AR interaction in vitro and in situ (Fig. 6e,f and Supplementary Fig. 6d,e ). Decreased AR signaling was also observed following blocking of this interaction ( Fig. 6g and Supplementary Fig. 6f ).
ARLNC1 regulates the cytoplasmic levels of AR transcripts.
We then sought to delineate the mechanism of ARLNC1-mediated AR regulation. We first monitored the stability of these two transcripts and found that AR and ARLNC1 have similar half-lives of ~9 h ( Supplementary Fig. 6g ). As ARLNC1 depletion resulted in a 
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NATURe GeNeTiCs striking reduction of AR protein levels, much more than could be explained by AR transcript reduction, we hypothesized that ARLNC1 could affect AR post-transcriptionally. To test this hypothesis, we tracked the subcellular localization of AR transcripts using smFISH after depleting ARLNC1. We confirmed successful in situ knockdown of ARLNC1 using siRNAs, antisense oligonucleotide (ASO) and the blocking oligonucleotides that targeted the ARLNC1-AR interaction (ASO-blocking) in MDA-PCa-2b cells ( Supplementary  Fig. 6h,i) . Quantification of the subcellular distribution of ARLNC1 suggested that the nuclear fraction of ARLNC1 was enriched only in the ARLNC1 siRNA (si-ARLNC1) condition ( Supplementary  Fig. 6j ), a result expected for siRNAs that are typically more functional in the cytosol 45 . Surprisingly, ARLNC1 knockdown or obstruction of the AR-ARLNC1 interaction increased the nuclear AR fraction by dramatically decreasing cytoplasmic levels of the AR transcript (Fig. 7a,b and Supplementary Fig. 6k-l) . This observation was further supported by BrU-seq and BrUChase-seq, two high-throughput tools that monitor transcript synthesis and stability. On ARLNC1 *** Articles NATURe GeNeTiCs knockdown, the synthesis rate of the AR transcript remained the same ( Supplementary Fig. 6m ), while the stability of the transcript decreased, particularly through the 3′ UTR ( Supplementary  Fig. 6n ). Taken together, our data suggest that ARLNC1 regulates the cytoplasmic levels of AR transcripts. Furthermore, the transcriptional coupling between AR and ARLNC1 transcripts is mediated by direct interactions that are encoded in their sequences.
Inhibition of ARLNC1 delays prostate cancer growth in vitro and in vivo.
Having established a role for ARLNC1 in the regulation of AR signaling, we further evaluated the biological effects of ARLNC1 in prostate cancer cell lines. GO pathway enrichment analysis of the knockdown microarray data showed that ARLNC1regulated genes were involved in cell proliferation and apoptosis (Fig. 4a ). Knockdown of ARLNC1 had a significant effect on the proliferation of AR-dependent MDA-PCa-2b and LNCaP cells, but had no effect on AR-negative DU145 and PC3 cells ( Fig. 8a and Supplementary Fig. 7a,b) . Knockdown of ARLNC1 also resulted in increased apoptosis in AR-positive prostate cancer cells ( Fig. 8b and Supplementary Fig. 7c ). Notably, these results translated to effects in vivo, as cells expressing shRNA targeting ARLNC1 formed smaller tumors in mice when compared to cells expressing non-targeting shRNA (Fig. 8c) , thus suggesting that ARLNC1 is an important survival factor for AR-dependent prostate cancer. Because modulation of ARLNC1 expression levels resulted in a striking proliferation phenotype, we hypothesized that ARLNC1 inhibition could be used therapeutically for the treatment of prostate cancer. ASOs have recently been shown to be effective in targeting RNA in vivo [46] [47] [48] [49] ; thus, we designed ASOs targeting the ARLNC1 transcript ( Supplementary Fig. 7d ). Transfection of ASOs resulted in strong knockdown efficiency ( Supplementary Fig. 7e) , and ASO-mediated knockdown resulted in similar effects on gene expression profiling to siRNA (Fig. 8d,e and Supplementary  Fig. 7f ). Furthermore, AR-positive cells transfected with ARLNC1 ASOs exhibited retarded growth, similar to those treated with siR-NAs (Fig. 8f) . To evaluate the therapeutic potential of ARLNC1 ASOs in vivo, we first assessed the cellular free-uptake efficiency of ARLNC1 ASOs, a prerequisite for ASO therapeutic use. Notably, several ASOs significantly reduced ARLNC1 levels through free uptake ( Supplementary Fig. 7g ). Free uptake of ARLNC1 ASOs led to a significant decrease in the proliferation capacity of MDA-PCa-2b cells in both normal cell culture and 3D sphere conditions ( Supplementary Fig. 7h-j) . Treatment of mice bearing MDA-PCa-2b xenografts with ARLNC1-targeting ASOs led to significant decreases in tumor growth compared to control ASO (Fig. 8g,h and Supplementary Fig. 8a-e ). Taken together, these data, along with the association of ARLNC1 with aggressive androgen signaling ( Supplementary Fig. 8f-j) , suggest that ARLNC1 plays a critical role in the proliferation of AR-dependent prostate cancer and can be effectively exploited as a therapeutic target.
Discussion
As AR signaling remains a significant driver of CRPC pathogenesis, it is imperative to generate novel strategies to target this pathway. Even with the addition of enzalutamide or abiraterone to CRPC treatment regimens, progression invariably occurs. Exploiting players other than AR itself that are pivotal to maintaining the magnitude of the androgen response is an alternative approach. Our comprehensive profiling of AR-regulated, prostate cancer-associated lncRNAs identified the top-ranking candidate ARLNC1 that we functionally characterized. We identified a positive feedback loop between ARLNC1 and AR that maintains the androgen transcriptional program in AR-positive prostate cancer cells, specifically through regulating the cellular levels of AR (Fig. 8i ). The mechanism we identified echoes previous studies on lncRNAs-1/2-sbsRNAs 42 , BACE1-AS 9 and TINCR 41 , which highlights the role of lncRNA in increasing or decreasing RNA stability.
As a novel noncoding regulator of AR signaling, ARLNC1 has the potential to be not only a mechanistic biomarker but also a therapeutic target for advanced prostate cancer. In addition, the fact that it acts upstream of AR signaling presents the possibility that targeting ARLNC1 may afford an additional option to patients that have de novo or acquired resistance to therapies targeting AR itself (that is, enzalutamide or abiraterone). Furthermore, specific antisense nucleotides targeting ARLNC1, which we demonstrate to be specifically expressed in the prostate, could circumvent undesirable side effects that occur in other tissues with exposure to androgen synthesis inhibitors or anti-androgens.
Although we have identified a new node of the AR signaling network that can be therapeutically targeted, the molecular mechanism through which ARLNC1 regulates AR transcript levels remains to be fully characterized. At this time, it is unclear whether the physical interaction between the AR 3′ UTR and ARLNC1 functions with the aid of additional RNA-binding proteins (for example, HuR) and/or RNAs in vivo 50, 51 . Nonetheless, the application of ASOs has ushered in an exciting era that makes it possible to target previously 'undruggable' molecules directly at the transcript level, such as ARLNC1, which is likely to yield promising opportunities in cancer treatment. 
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